Results 11 to 20 of about 7,079 (242)

Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity. [PDF]

Cancer Chemother Pharmacol, 2017
Liu C, Janke LJ, Yang JJ, Evans WE, Schuetz JD, Relling MV.   +5 more
europepmc   +3 more sources

Thiopurine methyltransferase activity in children with acute myeloid leukemia. [PDF]

Oncol Lett, 2018
Sobiak J, Skalska-Sadowska J, Chrzanowska M, Resztak M, Kołtan S, Wysocki M, Wachowiak J.   +6 more
europepmc   +3 more sources

Clinical implication of thiopurine methyltransferase polymorphism in children with acute lymphoblastic leukemia: A preliminary Egyptian study. [PDF]

Indian J Med Paediatr Oncol, 2015
El-Rashedy FH, Ragab SM, Dawood AA, Temraz SA.   +3 more
europepmc   +3 more sources

Utilizing a user-centered approach to develop and assess pharmacogenomic clinical decision support for thiopurine methyltransferase. [PDF]

BMC Med Inform Decis Mak, 2019
Nguyen KA, Nguyen KA, Patel H, Haggstrom DA, Zillich AJ, Imperiale TF, Russ AL.   +6 more
europepmc   +2 more sources

Pharmacogenomics of Thiopurine Drugs: A Bench-To-Bedside Success Story in Thailand. [PDF]

Clin Transl Sci
ABSTRACT Thiopurine drugs are the cornerstone treatment for many diseases such as acute lymphoblastic leukemia (ALL), organ rejection, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune diseases.
Biswas M, John S, Murad MA, Sukasem C.
europepmc   +2 more sources

Thiopurine S-Methyltransferase and Methylenetetrahydrofolate Reductase Polymorphisms in Leukemia

Turkish Journal of Hematology, 2015
Serhan Küpeli
doaj   +2 more sources

Genetic Determinants of Hematopoietic Toxicity Risk in Thai Pediatric Patients Undergoing 6-Mercaptopurine Treatment. [PDF]

Clin Transl Sci
ABSTRACT The nucleoside diphosphate‐linked moiety X‐type motif 15 (NUDT15) has been identified as a key genetic determinant of 6‐mercaptopurine (6‐MP)‐induced hematopoietic toxicity in populations with a high frequency of NUDT15 variants but a low frequency of thiopurine S‐methyltransferase (TPMT) variants.
Khaeso K, Chainansamit SO, Kuwatjanakul P, Komvilaisak P, Nakkam N, Suwannaying K, Vannaprasaht S, Dornsena A, Tassaneeyakul W.   +8 more
europepmc   +2 more sources

Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. [PDF]

Br J Haematol, 2015
Lennard L, Cartwright CS, Wade R, Vora A.   +3 more
europepmc   +3 more sources

Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. [PDF]

Clin Pharmacol Ther
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Thiopurines such as 6‐mercaptopurine (6MP) are essential in ALL maintenance therapy. However, dose‐limiting toxicities can significantly disrupt treatment. While genetic variants in TPMT and NUDT15 are known to affect thiopurine response, many patients with normal function ...
Bidoli C, Yang W, Karol SE, Lucafò M, Stocco G, Yang JJ.   +5 more
europepmc   +2 more sources

Economic evaluations of pharmacogenetic and pharmacogenomic screening tests : a systematic review : second update of the literature [PDF]

, 2016
Objective : Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature. Methods : A literature search was
Annemans, Lieven, Berm, Elizabeth JJ, Boersma, Cornelis, de Looff, Margot, Postma, Maarten J, van Boven, Job FM, Vegter, Stefan, Wilffert, Bob   +7 more
core   +15 more sources